Advertisement

Tumor Biology

, Volume 36, Issue 1, pp 453–458 | Cite as

Increased PTOV1 expression is related to poor prognosis in epithelial ovarian cancer

  • Fei Guo
  • Liu Feng
  • Ji-Long Hu
  • Mei-Ling Wang
  • Peng Luo
  • Xiao-Ming Zhong
  • An-Mei Deng
Research Article

Abstract

Altered expression of prostate tumor overexpressed-1 (PTOV1) is observed in various types of human cancers. However, the role of PTOV1 in epithelial ovarian cancer (EOC) remains unclear. PTOV1 messenger (m)RNA expression in EOC patients was evaluated by quantitative real-time PCR (qRT-PCR). PTOV1 protein expression was also analyzed in archived paraffin-embedded EOC tissues using immunohistochemistry (IHC), and its association with overall survival of patients was analyzed by statistical analysis. Results from qRT-PCR analysis show that the expression level of PTOV1 mRNA was significantly higher in tumor tissues of EOC, compared to that in adjacent noncancerous tissues (P < 0.001). IHC staining showed that high expression of PTOV1 was detected in 57.2 % (87/152) of EOC cases. High expression of PTOV1 was significantly associated with pathological grade (P = 0.029) and clinical stage (P = 0.001). Moreover, the results of Kaplan-Meier analysis indicated that a high expression level of PTOV1 resulted in a significantly poor prognosis of EOC patients. Multivariate analysis showed that high expression of PTOV1 was an independent prognostic factor for overall survival (P < 0.001). In conclusion, PTOV1 protein abnormal expression might contribute to the malignant progression of EOC. High expression of PTOV1 predicts poor prognosis in patients with EOC.

Keywords

PTOV1 EOC Biomarker Prognosis 

Notes

Acknowledgments

This research was supported by grant from 973 Foundation (2013CB531606).

Conflicts of interest

None

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi: 10.3322/caac.20107.CrossRefPubMedGoogle Scholar
  2. 2.
    Chen YL, Cheng WF, Chang MC, Lin HW, Huang CT, Chien CL, et al. Interferon-gamma in ascites could be a predictive biomarker of outcome in ovarian carcinoma. Gynecol Oncol. 2013;131:63–8. doi: 10.1016/j.ygyno.2013.07.105.CrossRefPubMedGoogle Scholar
  3. 3.
    White KL, Schildkraut JM, Palmieri RT, Iversen Jr ES, Berchuck A, Vierkant RA, et al. Ovarian cancer risk associated with inherited inflammation-related variants. Cancer Res. 2012;72:1064–9. doi: 10.1158/0008-5472.CAN-11-3512.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Koyanagi T, Suzuki Y, Saga Y, Machida S, Takei Y, Fujiwara H, et al. In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer. Cancer Sci. 2013;104:1705–10. doi: 10.1111/cas.12297.CrossRefPubMedGoogle Scholar
  5. 5.
    Tsofack SP, Meunier L, Sanchez L, Madore J, Provencher D, Mes-Masson AM, et al. Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis. BMC Cancer. 2013;13:303. doi: 10.1186/1471-2407-13-303.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Marsh S. Pharmacogenomics of taxane/platinum therapy in ovarian cancer. Int J Gynecol Cancer. 2009;19 Suppl 2:S30–4. doi: 10.1111/IEOC.0b013e3181c10513.CrossRefPubMedGoogle Scholar
  7. 7.
    Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res. 2001;478:23–43.CrossRefPubMedGoogle Scholar
  8. 8.
    Morote J, Fernández S, Alaña L, Iglesias C, Planas J, Reventós J, et al. PTOV1 expression predicts prostate cancer in men with isolated high-grade prostatic intraepithelial neoplasia in needle biopsy. Clin Cancer Res. 2008;14:2617–22.CrossRefPubMedGoogle Scholar
  9. 9.
    Santamaría A, Fernández PL, Farré X, Benedit P, Reventós J, Morote J, et al. PTOV-1, a novel protein overexpressed in prostate cancer, shuttles between the cytoplasm and the nucleus and promotes entry into the S phase of the cell division cycle. Am J Pathol. 2003;162:897–905. doi: 10.1016/S0002-9440(10)63885-0.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Yousef GM, Luo LY, Diamandis EP. Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4. Anticancer Res. 1999;19:2843–52.PubMedGoogle Scholar
  11. 11.
    Schierup MH, Mailund T, Li H, Wang J, Tjønneland A, Vogel U, et al. Haplotype frequencies in a sub-region of chromosome 19q13.3, related to risk and prognosis of cancer, differ dramatically between ethnic groups. BMC Med Genet. 2009;10:20.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Benedit P, Paciucci R, Thomson TM, Valeri M, Nadal M, Càceres C, et al. PTOV1, a novel protein overexpressed in prostate cancer containing a new class of protein homology blocks. Oncogene. 2001;20:1455–64.CrossRefPubMedGoogle Scholar
  13. 13.
    Fernández S, Mosquera JL, Alaña L, Sanchez-Pla A, Morote J, Ramón Y, et al. PTOV1 is overexpressed in human high-grade malignant tumors. Virchows Arch. 2011;458:323–30. doi: 10.1007/s00428-010-1018-1.CrossRefPubMedGoogle Scholar
  14. 14.
    Lei F, Zhang L, Li X, Lin X, Wu S, Li F, et al. Overexpression of prostate tumor overexpressed 1 correlates with tumor progression and predicts poor prognosis in breast cancer. BMC Cancer. 2014;14:457. doi: 10.1186/1471-2407-14-457.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Konstantinopoulos PA, Matulonis UA. Current status and evolution of preclinical drug development models of epithelial ovarian cancer. Front Oncol. 2013;3:296. doi: 10.3389/fonc.2013.00296.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Gynecology and ObstetricsTianjin Medical University General HospitalTianjinChina
  2. 2.Department of OncologyNo. 3 People’s Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghaiChina
  3. 3.Department of Oncological SurgeryJiangxi Tumor HospitalNanchangChina
  4. 4.TopGen Diagnostics Co., LtdShanghaiChina
  5. 5.Department of Tumor Radiotherapy and ChemotherapyJiangxi Tumor HospitalNanchangChina
  6. 6.Department of Laboratory DiagnosisChanghai Hospital Affiliated to the Second Military Medical UniversityShanghaiChina

Personalised recommendations